The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Clinical implications of the intrinsic molecular subtypes of breast cancer
Open accessAbstract
Gene-expression profiling has had a considerable impact on our understanding of breast cancer biology. During the last 15 years, 5 intrinsic molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-enriched, Basal-like and Claudin-low) have been identified and intensively studied. In this review, we will focus on the current and future clinical implications of the intrinsic molecular subtypes beyond the current pathological-based classification endorsed by the 2013 St. Gallen Consensus Recommendations. Within hormone receptor-positive and HER2-negative early breast cancer, the Luminal A and B subtypes predict 10-year outcome regardless of systemic treatment administered as well as residual risk of distant recurrence after 5 years of endocrine therapy. Within clinically HER2-positive disease, the 4 main intrinsic subtypes can be identified and dominate the biological and clinical phenotype. From a clinical perspective, patients with HER2+/HER2-enriched disease seem to benefit the most from neoadjuvant trastuzumab, or dual HER2 blockade with trastuzumab/lapatinib, in combination with chemotherapy, and patients with HER2+/Luminal A disease seem to have a relative better outcome compared to the other subtypes. Finally, within triple-negative breast cancer (TNBC), the Basal-like disease predominates (70-80%) and, from a biological perspective, should be considered a cancer-type by itself. Importantly, the distinction between Basal-like versus non-Basal-like within TNBC might predict survival following (neo)adjvuvant multi-agent chemotherapy, bevacizumab benefit in the neoadjuvant setting (CALGB40603), and docetaxel vs. carboplatin benefit in first-line metastatic disease (TNT study). Overall, this data suggests that intrinsic molecular profiling provides clinically relevant information beyond current pathology-based classifications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Hammond, M. E. H., Hayes, D. F., Dowsett, M., Allred, D. C., Hagerty, K. L., Badve, S., Fitzgibbons, P. L., Francis, G., Goldstein, N. S., Hayes, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6529 · Cited by 4,213
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,030
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp082 · Cited by 2,249
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Self-citationEarly Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Dowsett, M., Nielsen, T. O., A'Hern, R., Bartlett, J., Coombes, R. C., Cuzick, J., Ellis, M., Henry, N. L., Hugh, J. C., Lively, T., et al. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr393 · Cited by 1,977
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
kConFab, Lim, E., Vaillant, F., Wu, D., Forrest, N. C., Pal, B., Hart, A. H., Asselin-Labat, M.-L., Gyorki, D. E., Ward, T., et al. (2009) · Nature Medicine · doi:10.1038/nm.2000 · Cited by 1,492
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Self-citationLoi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Roberts, S. A., Lawrence, M. S., Klimczak, L. J., Grimm, S. A., Fargo, D., Stojanov, P., Kiezun, A., Kryukov, G. V., Carter, S. L., Saksena, G., et al. (2013) · Nature Genetics · doi:10.1038/ng.2702 · Cited by 1,167
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Sledge, G., Geyer, C. E., Martino, S., Rastogi, P., Gralow, J., Swain, S. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5730 · Cited by 978
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Epidemiology of basal-like breast cancer
Millikan, R. C., Newman, B., Tse, C.-K., Moorman, P. G., Conway, K., Smith, L. V., Labbok, M. H., Geradts, J., Bensen, J. T., Jackson, S., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9632-6 · Cited by 886
Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., Davies, S. R., Snider, J., Stijleman, I. J., Reed, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1282 · Cited by 801
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Molyneux, G., Geyer, F. C., Magnay, F.-A., McCarthy, A., Kendrick, H., Natrajan, R., MacKay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.07.010 · Cited by 794
Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
Ali, H. R., Provenzano, E., Dawson, S.-J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, L., Dunn, J. A., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu191 · Cited by 774
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J.-H., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kaufman, P. A., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0868 · Cited by 717
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn309 · Cited by 653
Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., Ferree, S., Storhoff, J., Schaper, C., & Cuzick, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1558 · Cited by 621
Prat, A., Cheang, M. C. U., Martín, M., Parker, J. S., Carrasco, E., Caballero, R., Tyldesley, S., Gelmon, K., Bernard, P. S., Nielsen, T. O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4134 · Cited by 587
Self-citationMolecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
Self-citationCancer mortality in Europe, 2000–2004, and an overview of trends since 1975
La Vecchia, C., Bosetti, C., Lucchini, F., Bertuccio, P., Negri, E., Boyle, P., & Levi, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp530 · Cited by 559
Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6950 · Cited by 551
Self-citationHugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1024 · Cited by 526
Lehmann, B. D., & Pietenpol, J. A. (2014) · The Journal of Pathology · doi:10.1002/path.4280 · Cited by 495
Gianni, L., Eiermann, W., Semiglazov, V., Lluch, A., Tjulandin, S., Zambetti, M., Moliterni, A., Vazquez, F., Byakhov, M. J., Lichinitser, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70080-4 · Cited by 490
de Azambuja, E., Holmes, A. P., Piccart-Gebhart, M., Holmes, E., Di Cosimo, S., Swaby, R. F., Untch, M., Jackisch, C., Lang, I., Smith, I., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70320-1 · Cited by 458
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
von Minckwitz, G., Blohmer, J. U., Costa, S. D., Denkert, C., Eidtmann, H., Eiermann, W., Gerber, B., Hanusch, C., Hilfrich, J., Huober, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0940 · Cited by 414
PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers
Bastien, R. R., Rodríguez-Lescure, Á., Ebbert, M. T., Prat, A., Munárriz, B., Rowe, L., Miller, P., Ruiz-Borrego, M., Anderson, D., Lyons, B., et al. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-44 · Cited by 334
Self-citationChia, S. K., Bramwell, V. H., Tu, D., Shepherd, L. E., Jiang, S., Vickery, T., Mardis, E., Leung, S., Ung, K., Pritchard, K. I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0286 · Cited by 302
Practical implications of gene-expression-based assays for breast oncologists
Prat, A., Ellis, M. J., & Perou, C. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.178 · Cited by 295
Self-citationIwamoto, T., Booser, D., Valero, V., Murray, J. L., Koenig, K., Esteva, F. J., Ueno, N. T., Zhang, J., Shi, W., Qi, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2574 · Cited by 288
Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutierrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274
How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
Anderson, W. F., Rosenberg, P. S., Prat, A., Perou, C. M., & Sherman, M. E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju165 · Cited by 265
Self-citationSestak, I., Cuzick, J., Dowsett, M., Lopez-Knowles, E., Filipits, M., Dubsky, P., Cowens, J. W., Ferree, S., Schaper, C., Fesl, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6894 · Cited by 249
Defining the cellular precursors to human breast cancer
Keller, P. J., Arendt, L. M., Skibinski, A., Logvinenko, T., Klebba, I., Dong, S., Smith, A. E., Prat, A., Perou, C. M., Gilmore, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017626108 · Cited by 233
Self-citationPrat, A., Carey, L. A., Adamo, B., Vidal, M., Tabernero, J., Cortés, J., Parker, J. S., Perou, C. M., & Baselga, J. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju152 · Cited by 233
Self-citationPrat, A., Bianchini, G., Thomas, M., Belousov, A., Cheang, M. C. U., Koehler, A., Gómez, P., Semiglazov, V., Eiermann, W., Tjulandin, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0239 · Cited by 229
Self-citationMackey, J. R., Martin, M., Pienkowski, T., Rolski, J., Guastalla, J.-P., Sami, A., Glaspy, J., Juhos, E., Wardley, A., Fornander, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70525-9 · Cited by 224
Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
Sestak, I., Dowsett, M., Zabaglo, L., Lopez-Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt244 · Cited by 222
Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stöger, H., Jakesz, R., Bago-Horvath, Z., Dietze, O., Regitnig, P., Gruber-Rossipal, C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1845 · Cited by 215
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn005 · Cited by 197
Prat, A., Parker, J. S., Fan, C., & Perou, C. M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2143-0 · Cited by 194
Self-citationTutt, A., Ellis, P., Kilburn, L., Gilett, C., Pinder, S., Abraham, J., Barrett, S., Barrett-Lee, P., Chan, S., Cheang, M., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s3-01 · Cited by 167
Piccart, M. J., Holmes, A., Baselga, J. M., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Santillana, S., Pritchard, K. I., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.18_suppl.lba4 · Cited by 154
Vaz-Luís, I., Ottesen, R. A., Hughes, M. E., Marcom, P. K., Moy, B., Rugo, H. S., Theriault, R. L., Wilson, J. L., Niland, J. C., Weeks, J. C., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3324 · Cited by 143
Cheang, M. C. U., Voduc, K. D., Tu, D., Jiang, S., Leung, S. C. Y., Chia, S., Shepherd, L. E., Levine, M. N., Pritchard, K. I., Davies, S. R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2956 · Cited by 143
Prat, A., Parker, J. S., Fan, C., Cheang, M. C. U., Miller, L. D., Bergh, J. C. S., Chia, S., Bernard, P. S., Nielsen, T. O., Ellis, M. J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds080 · Cited by 141
Self-citationPredicting response and survival in chemotherapy-treated triple-negative breast cancer
Prat, A., Lluch, A. M., Albanell, J., Barry, W. T., Fan, C., Chacón, J. I., Parker, J. S., Calvo, L., Plazaola, A., Arcusa, À., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.444 · Cited by 132
Self-citationPogue–Geile, K. L., Song, N., Jeong, J., Gavin, P. G., Kim, S.-R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2439 · Cited by 119
APOBEC3B mutagenesis in cancer
Kuong, K. J., & Loeb, L. A. (2013) · Nature Genetics · doi:10.1038/ng.2736 · Cited by 110
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Martín, M., Prat, A., Rodríguez-Lescure, Á., Caballero, R., Ebbert, M., Munárriz, B., Ruíz-Borrego, M., Bastien, R. R. L., Crespo, C., Davis, C. A., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2416-2 · Cited by 103
Self-citationPredicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
Usary, J., Zhao, W., Darr, D. B., Roberts, P. J., Liu, M., Balletta, L., Karginova, O. A., Jordan, J. L., Combest, A. J., Bridges, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0522 · Cited by 71
Self-citationIs Adjuvant Chemotherapy Useful for Women With Luminal A Breast Cancer?
Coates, A. S., Colleoni, M. A., & Goldhirsch, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7879 · Cited by 67
McCullough, A. E., Dell’Orto, P., Reinholz, M. M., Gelber, R. D., Dueck, A. C., Russo, L., Jenkins, R. B., Andrighetto, S., Chen, B., Jackisch, C., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2827-0 · Cited by 66
Prat, A., Adamo, B., Fan, C., Peg, V., Vidal, M. J., Galván, P., Vivancos, A. P., Nuciforo, P. G., Pálmer, H. G., Dawood, S. S., et al. (2013) · Scientific Reports · doi:10.1038/srep03544 · Cited by 64
Self-citationAssociation between breast cancer subtypes and response to neoadjuvant anastrozole
Dunbier, A. K., Anderson, H., Ghazoui, Z. F., Salter, J., Parker, J. S., Perou, C. M., Smith, I. E., & Dowsett, M. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.025 · Cited by 60
Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status
Prat, A., Cruz, C., Hoadley, K. A., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3056-x · Cited by 47
Self-citationPrat, A., & Baselga, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4998 · Cited by 28
Self-citationSikov, W. M., Barry, W. T., Hoadley, K. A., Pitcher, B. N., Singh, B., Tolaney, S. M., Kuzma, C. S., Pluard, T., Somlo, G., Port, E. R., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s4-05 · Cited by 19
EIERMANN, W., Baselga, J. M., Семиглазов, В. Ф., Byakhov, M. J., Ciruelos, E., Ojeda, B., Feyereislova, A., Zambetti, M., Valagussa, P., & Gianni, L. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)70544-5 · Cited by 6
Cited by
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
Braman, N. M., Etesami, M., Prasanna, P., Dubchuk, C., Gilmore, H., Tiwari, P., Plecha, D., & Madabhushi, A. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0846-1 · Cited by 632
Drug Combinations in Breast Cancer Therapy
Fisusi, F. A., & Akala, E. O. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190122111224 · Cited by 449
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
Metadata
- Authors
- Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M.
- Venue
- The Breast
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 24
- Pages
- S26-S35
- ISSN
- 0960-9776 (ISSN-L)
- OpenAlex
- W2141414987
- Cited by
- 1,319
- References
- 85
- FWCI
- 16.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.